Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs

Guerin, 2002, Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda, Lancet Infect. Dis., 2, 494, 10.1016/S1473-3099(02)00347-X

Davies, 2003, Leishmaniasis: new approaches to disease control, BMJ, 326, 377, 10.1136/bmj.326.7385.377

Zilberstein, 1993, Transport of nutrients and ions across membranes of trypanosomatid parasites, Adv. Parasitol., 32, 261, 10.1016/S0065-308X(08)60209-2

Burchmore, 2001, Life in vacuoles–nutrient acquisition by Leishmania amastigotes, Int. J. Parasitol., 31, 1311, 10.1016/S0020-7519(01)00259-4

Sundar, 2001, Drug resistance in Indian visceral leishmaniasis, Trop. Med. Int. Health, 6, 849, 10.1046/j.1365-3156.2001.00778.x

Berhe, 1999, HIV viral load and response to antileishmanial chemotherapy in co-infected patients, AIDS, 13, 1921, 10.1097/00002030-199910010-00015

1995

Moore, 2001, Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya, Bull. World Health Organ., 79, 388

Thakur, 1999, Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases, Trans. R. Soc. Trop. Med. Hyg., 93, 319, 10.1016/S0035-9203(99)90037-8

Berman, 1998, Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries, Bull. World Health Organ., 76, 25

Meyerhoff, 1999, U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis, Clin. Infect. Dis., 28, 49, 10.1086/515085

Sundar, 2001, Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial, BMJ, 323, 419, 10.1136/bmj.323.7310.419

Bodhe, 1999, Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis, Trans. R. Soc. Trop. Med. Hyg., 93, 314, 10.1016/S0035-9203(99)90036-6

Petit, 1999, Activity of heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani, Antimicrob. Agents Chemother., 43, 390, 10.1128/AAC.43.2.390

Croft, 2003, Antiprotozoal activities of phospholipid analogues, Mol. Biochem. Parasitol., 126, 165, 10.1016/S0166-6851(02)00283-9

Sundar, 2002, Oral miltefosine for Indian visceral leishmaniasis, N. Engl. J. Med., 347, 1739, 10.1056/NEJMoa021556

Soto, 2001, Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent, Clin. Infect Dis., 33, E57, 10.1086/322689

Yeates, 2002, Sitamaquine (GlaxoSmithKline / Walter Reed Army Institute), Curr. Opin. Investig. Drugs, 3, 1446

Dietze, 2001, Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi, Am. J. Trop. Med. Hyg., 65, 685, 10.4269/ajtmh.2001.65.685

Thakur, 2000, Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study, Trans. R. Soc. Trop. Med. Hyg., 94, 432, 10.1016/S0035-9203(00)90131-7

El-On, 1992, Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study, J. Am. Acad. Dermatol., 27, 227, 10.1016/0190-9622(92)70175-F

Soto, 2002, Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study, Am. J. Trop. Med. Hyg., 66, 147, 10.4269/ajtmh.2002.66.147

Garnier, 2002, Topical treatment for cutaneous leishmaniasis, Curr. Opin. Investig. Drugs, 3, 538

Koutinas, 2001, A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniasis, Vet. Parasitol., 98, 247, 10.1016/S0304-4017(01)00399-5

Navin, 1992, Placebo-controlled trial of sodium stibogluconate (Pentostam) versus ketoconazole in Guatemala, J. Infect Dis., 165, 528, 10.1093/infdis/165.3.528

Al-Abdely, 1999, Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis, Antimicrob. Agents Chemother., 43, 2910, 10.1128/AAC.43.12.2910

Rodriguez, 2002, Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate, J. Infect Dis., 186, 138, 10.1086/341074

Yardley, 2002, In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii, Antimicrob. Agents Chemother., 46, 929, 10.1128/AAC.46.3.929-931.2002

Martin, 2001, Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy, J. Med. Chem., 44, 909, 10.1021/jm0002578

Zhai, 1999, The antileishmanial activity of novel oxygenated chalcones and their mechanism of action, J. Antimicrob. Chemother., 43, 793, 10.1093/jac/43.6.793

Fournet, 1996, In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of New World cutaneous leishmaniasis caused by Leishmania amazonensis, Antimicrob. Agents Chemother., 40, 2447, 10.1128/AAC.40.11.2447

Olliaro, 2002, Developments in the treatment of leishmaniasis and trypanosomiasis, Expert Opin. Emerging Drugs, 7, 1, 10.1517/14728214.7.1.61

Murray, 1989, Requirement for T cells and effects of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis, J. Clin. Invest., 83, 1253, 10.1172/JCI114009

Alvar, 1997, Leishmania and human immunodeficiency virus co-infection: the first 10 years, Clin. Microbiol. Rev., 10, 298, 10.1128/CMR.10.2.298

Buates, 1999, Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action, J. Infect Dis., 179, 1485, 10.1086/314782

Arevalo, 2001, Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator, Clin. Infect Dis., 33, 1847, 10.1086/324161

Lopez-Jaramillo, 1998, Treatment of cutaneous leishmaniasis with nitric oxide donor, Lancet, 351, 1176, 10.1016/S0140-6736(05)79119-4

Smith, 2000, Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis, Antimicrob. Agents Chemother., 44, 1494, 10.1128/AAC.44.6.1494-1498.2000

Awasthi, 2003, CD40 signaling is impaired by L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response, J. Exp. Med., 197, 1037, 10.1084/jem.20022033

Barrett, 1999, Recent advances in identifying and validating drug targets in trypanosomes and leishmanias, Trends Microbiol., 7, 82, 10.1016/S0966-842X(98)01433-4

Fries, 2003, Antiprotozoal agents, Vol. 5, 1033

Sajid, 2002, Cysteine proteases of parasitic organisms, Mol. Biochem. Parasitol., 120, 1, 10.1016/S0166-6851(01)00438-8

Roberts, 2003, Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa, Mol. Biochem. Parasitol., 126, 129, 10.1016/S0166-6851(02)00280-3

Gilbert, 2002, Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes, Biochim. Biophys. Acta, 1587, 249, 10.1016/S0925-4439(02)00088-1

Cunningham, 2001, Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy, Mol. Biochem. Parasitol., 113, 199, 10.1016/S0166-6851(01)00213-4

Gelb, 2003, Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics, Mol. Biochem. Parasitol., 126, 155, 10.1016/S0166-6851(02)00282-7

Verlinde, 2001, Glycolysis as a target for the design of new anti-trypanosome drugs, Drug Resist. Updat., 4, 50, 10.1054/drup.2000.0177

Müller, 2001, Targeting polyamines of parasitic protozoa in chemotherapy, Trends Parasitol., 17, 242, 10.1016/S1471-4922(01)01908-0

Doerig, 2002, Protein kinases as drug targets in parasitic protozoa, Trends Parasitol., 18, 366, 10.1016/S1471-4922(02)02321-8

Havens, 2000, Cellular effects of leishmanial tubulin inhibitors on L. donovani, Mol. Biochem. Parasitol., 110, 223, 10.1016/S0166-6851(00)00272-3

Jayanarayan, 2002, Microtubules: dynamics, drug interaction and drug resistance in Leishmania, J. Clin. Pharm. Ther., 27, 313, 10.1046/j.1365-2710.2002.00431.x

Roberts, 1998, Characterization of the antimonial antileishmanial agent meglumine antimonate (Glucantime), Antimicrob. Agents Chemother., 42, 1076, 10.1128/AAC.42.5.1076

Zilberstein, 2002, Clinical and laboratory aspects of Leishmania chemotherapy in the area of drug resistance, Vol. 4, 115

Pathak, 2001, Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines, J. Immunol., 167, 3391, 10.4049/jimmunol.167.6.3391

Croft, 2002, Chemotherapy of leishmaniasis, Curr. Pharm. Des., 8, 319, 10.2174/1381612023396258

Croft, 2001, Monitoring drug resistance in leishmaniasis, Trop. Med. Int. Health, 6, 899, 10.1046/j.1365-3156.2001.00754.x

Lira, 1999, Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani, J. Infect Dis., 180, 564, 10.1086/314896